Predictive value of post-treatment C-reactive protein-to-albumin ratio in locally advanced non-small cell lung cancer patients receiving durvalumab after chemoradiotherapy.
Taisuke ArakiKazunari TateishiMasamichi KomatsuKei SoneharaSatoshi WasamotoShigeru KoyamaFumiaki YoshiikeMineyuki HamaKenichi NishieDaichi KondoToshihiko AgatsumaAkane KatoMunetake TakataShintaro KandaMasayuki HanaokaTomonobu KoizumiPublished in: Thoracic cancer (2022)
This study suggests that post-treatment CAR has predictive value for LA-NSCLC patients treated with CCRT plus durvalumab consolidation therapy.